Efficacy And Safety Of The Anti-Epidermal Growth Factor Antibody (EGFR) IMC-C225, In Combination With Cisplatin In Patients With Recurrent Squamous Cell Carcinoma Of The Head And Neck (SCCHN) Refractory To Cisplatin Containing Chemotherapy
Diana Stripp, MD
University of Pennsylvania Cancer
Last Modified: May 13, 2001
Presenter: Waun Ki Hong/Roy S. Herbst
Affiliation: Anderson Cancer Center
- Patients with recurrent SCCHN who fail to respond to platinum-based therapy rarely respond to second-line treatment
- This study was performed to evaluate IMC-C225 in patients that have failed standard chemotherapy.
Materials and Methods:
- Patients (pts) with recurrent SCCHN received 2 cycles of a cisplatin (CDDP) containing regimen.
- Those with either progressive or stable disease went on to receive CDDP + IMC-C225 (41 patients).
- Pts received IMC-C225, 400 mg/m2 loading dose followed by 250 mg/m2, weekly, plus intravenous cDDP at the same dose and schedule previously administered.
- This study only addresses the 41 patients with stable disease who went on to receive CDDP+IMC-C225
- Seventy-five percent of the patients were male, the mean age was 54.4 years (range 39-76 years)
- The most commonly reported adverse events related to IMC-C225 therapy were folliculitis/acne and allergic reactions (5%).
- Ten (24%) patients achieved an objective response to therapy (one complete response and nine partial responses), and 25 (61%) patients maintained stable disease.
- The trial for the progressive disease subgroup is still ongoing and will be presented at a future time.
- IMC-C225 in combination with CDDP appears to be well tolerated and the response rate suggests clinical activity for this combination of biologic and cytotoxic therapy.
- IMC-C225 has potential for treatment of all advanced stage of disease
- In analyses of the 22 pts with progression of disease after the induction chemotherapy regimen which were not reported in the abstract, it was reported 23% achieved an objective response to therapy.
- This is a promising molecular targeting strategy that has potential to become and important avenue for cancer treatment in the future.
OncoLink ASCO 2001 coverage is provided by an unrestricted educational grant from Amgen
Frequently Asked Questions
National Cancer Institute